Melanoma circulating tumor cells: Benefits and challenges required for clinical application

The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and co...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2018-06, Vol.424, p.1-8
Main Authors: Marsavela, G., Aya-Bonilla, C.A., Warkiani, M.E., Gray, E.S., Ziman, M.
Format: Article
Language:English
Subjects:
Antigens
Biomarker
Biomarkers
Biomarkers, Tumor - metabolism
Biopsy
Blood
Breast cancer
Cancer
Cell adhesion & migration
Cell Separation
Cells
Circulating tumor cells
Colorectal cancer
Drug resistance
FDA approval
Female
Humans
Immunoglobulins
Kinases
Laboratories
Liquid biopsy
Male
Medical prognosis
Medical research
Melanoma
Melanoma - blood
Melanoma - metabolism
Melanoma - pathology
Metastases
Metastasis
Neoplastic Cells, Circulating - metabolism
Neoplastic Cells, Circulating - pathology
Patients
Prostate
Prostate cancer
Proteins
Standardization
Therapeutic applications
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management. •This review discusses Melanoma CTCs (MelCTCs).•MelCTCs are promising liquid biopsy biomarkers in melanoma.•They are heterogeneous with no common marker for their detection, unlike epithelial cancers.•Label-independent methods are preferred for isolation of diverse MelCTCs.•Identification of MelCTC subtypes provides significant clinical utility.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2018.03.013